Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders
Condition(s) studied
Investigational drug(s) / intervention(s)
Digital: Kiso Mind App: See above.
Study summary
The Kiso pilot study is a randomized controlled trial to test the acceptability and feasibility of a novel digital intervention, namely the Kiso Mind smartphone app. A parallel-group design is utilized. Participants either receive access to the Kiso Mind intervention and treatment-as-usual (TAU) in the experimental condition or receive treatment as usual (TAU) in the control condition. The intervention is designed for participants diagnosed with either schizophrenia (F20.0) or schizoaffective disorder (F25.0) according to the ICD-10.
To examine acceptability, feasibility, and preliminary effectiveness, both self-report and rater-based assessments are administered at baseline (T0) and at the end of the 12-week intervention period (post-intervention T1). Lastly, a qualitative interview will be conducted with participants from the experimental condition. The primary outcome of the present study is the acceptability and feasibility of the Kiso Mind app. The secondary outcome consists of general psychopathology, and positive-, negative-, depressive symptoms, as well as social functioning and self-efficacy ratings.
Eligibility
Primary outcome measure(s)
- Proportion of PP receiving threshold dose (Acceptability) — 12 weeks
The proportion of modules completed on average by all participants. - Nr. of pp willing to participate (Feasibility) — 12 weeks
The number of eligible participants, that are willing to participate in Kiso (recruitment)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Charité - Universitätsmedizin Berlin | Berlin | State of Berlin | Recruiting |
More Charite University, Berlin, Germany trials in Germany
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07395206 on ClinicalTrials.gov ↗ ← All trials in Germany